Tilray Brands (TLRY) Long-Term Deferred Tax (2018 - 2025)
Tilray Brands (TLRY) reported Long-Term Deferred Tax of $42.3 million for Q2 2025, down 62.74% on a YoY basis from $113.6 million in Q2 2024, and down 62.74% quarter-over-quarter from $113.6 million in Q2 2024.
Tilray Brands (TLRY) Long-Term Deferred Tax (2018 - 2025) Analysis & Trends
Tilray Brands has reported Long-Term Deferred Tax for 3 years, with the latest figure at $42.3 million in Q2 2025.
- For the quarter ending Q2 2025, Long-Term Deferred Tax fell 62.74% year-over-year to $42.3 million; the trailing twelve-month figure through May 2025 stood at $42.3 million (down 62.74% YoY), and the FY2025 full-year result was $42.3 million, down 62.74% from the prior year.
- Long-Term Deferred Tax for Q2 2025 stood at $42.3 million, down from $113.6 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $113.6 million in Q2 2024, with the low at $42.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Tilray Brands | - | - | 54.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | 42.34 Mn |
| May 31, 2024 | 113.63 Mn |
| Dec 31, 2018 | 27,000.00 |